Hutchison China Meditech Limited Blocklisting Six Monthly Return (4737J)

TIDMHCM

RNS Number : 4737J

Hutchison China Meditech Limited

29 June 2017

Blocklisting Six Monthly Return

London: Thursday, June 29, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:

 
1.   Name of applicant:                Hutchison China MediTech 
                                        Limited 
2.   Name of scheme:                   Hutchison China MediTech 
                                        Limited Share Option 
                                        Schemes 
3.   Period of return:                 From December 29, 2016 
                                        to June 28, 2017 
4.   Balance under scheme              1,361,308 ordinary shares 
      from previous return:             of US$1 each 
5.   The amount by which the           Nil 
      block scheme has been 
      increased, if the scheme 
      has been increased since 
      the date of the last 
      return: 
6.   Number of securities              31,381 ordinary shares 
      issued/allotted under             of US$1 each 
      scheme during period: 
7.   Balance under scheme              1,329,927 ordinary shares 
      not yet issued/allotted           of US$1 each 
      at end of the period: 
8.   Number and class of securities    2,560,606 ordinary shares 
      originally listed and             of US$1 each admitted 
      the date of admission:            on June 26, 2007 
9.   Total number of securities        60,737,204 ordinary 
      in issue at the end of            shares of US$1 each 
      the period: 
 
Name of contact:                       Christian Hogg 
Address of contact:                    21/F., Hutchison House, 
                                        10 Harcourt Road, Hong 
                                        Kong 
Telephone number of contact:           [phone] 
 

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
Christian Hogg, CEO                        [phone] 
 
U.K. & International Media Enquiries 
Anthony Carlisle, Citigate Dewe Rogerson   [phone] (Mobile)   [e-mail] 
 
U.S. Based Media Enquiries 
Brad Miles, BMC Communications             [phone] (Mobile)  [e-mail] 
Susan Duffy, BMC Communications            [phone] (Mobile)  [e-mail] 
 
Investor Relations 
Matt Beck, The Trout Group                 [phone] (Mobile)  [e-mail] 
David Dible, Citigate Dewe Rogerson        [phone] (Mobile)   [e-mail] 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts                [phone] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRUWOSRBVANUAR

(END) Dow Jones Newswires

June 29, 2017 02:01 ET (06:01 GMT)